Tags

Type your tag names separated by a space and hit enter

FGFR1 amplification in squamous cell carcinoma of the lung.
J Thorac Oncol. 2012 Dec; 7(12):1775-1780.JT

Abstract

INTRODUCTION

Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification.

METHODS

The study is an Institutional Review Board approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital from 2005 to 2011. Clinical and demographic characteristics of all patients were obtained, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. fluorescence in situ hybridization was performed for FGFR1 on formalin-fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available.

RESULTS

Thirty-seven of 226 patients (16%) with squamous cell lung cancer were found positive for amplification using a definition of amplification of a gene to copy number control ratio of 2.2 or higher. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history, or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive because of the small sample size.

CONCLUSION

FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancer patients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cell patients should be tested for this genomic change.

Authors+Show Affiliations

Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Electronic address: rheist@partners.org.Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.Department of Pulmonary Medicine, Massachusetts General Hospital, Boston, Massachusetts.Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23154548

Citation

Heist, Rebecca S., et al. "FGFR1 Amplification in Squamous Cell Carcinoma of the Lung." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 7, no. 12, 2012, pp. 1775-1780.
Heist RS, Mino-Kenudson M, Sequist LV, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012;7(12):1775-1780.
Heist, R. S., Mino-Kenudson, M., Sequist, L. V., Tammireddy, S., Morrissey, L., Christiani, D. C., Engelman, J. A., & Iafrate, A. J. (2012). FGFR1 amplification in squamous cell carcinoma of the lung. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 7(12), 1775-1780. https://doi.org/10.1097/JTO.0b013e31826aed28
Heist RS, et al. FGFR1 Amplification in Squamous Cell Carcinoma of the Lung. J Thorac Oncol. 2012;7(12):1775-1780. PubMed PMID: 23154548.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FGFR1 amplification in squamous cell carcinoma of the lung. AU - Heist,Rebecca S, AU - Mino-Kenudson,Mari, AU - Sequist,Lecia V, AU - Tammireddy,Swathi, AU - Morrissey,Laura, AU - Christiani,David C, AU - Engelman,Jeffrey A, AU - Iafrate,A John, PY - 2012/11/17/entrez PY - 2012/11/17/pubmed PY - 2013/5/8/medline SP - 1775 EP - 1780 JF - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer JO - J Thorac Oncol VL - 7 IS - 12 N2 - INTRODUCTION: Amplification of fibroblast growth factor receptor 1 (FGFR1) has been reported in squamous cell lung carcinoma and may be a molecular target for therapy. Little is known, however, about the clinical and demographic correlates of FGFR1 amplification. METHODS: The study is an Institutional Review Board approved retrospective analysis of 226 patients with squamous cell lung cancer seen at the Massachusetts General Hospital from 2005 to 2011. Clinical and demographic characteristics of all patients were obtained, as well as treatment details including surgery, radiation, and chemotherapy, and overall survival. fluorescence in situ hybridization was performed for FGFR1 on formalin-fixed paraffin-embedded tumor tissue. Clinical genotyping results were also reviewed where available. RESULTS: Thirty-seven of 226 patients (16%) with squamous cell lung cancer were found positive for amplification using a definition of amplification of a gene to copy number control ratio of 2.2 or higher. FGFR1 amplification status was not associated with age, sex, stage, histologic subtype within squamous cell, smoking history, or pack-years of smoking. We found no significant difference in overall survival by FGFR1 amplification status as a whole; in the advanced stage subset, our findings are inconclusive because of the small sample size. CONCLUSION: FGFR1 amplification was found in 16% of a clinical cohort of squamous cell lung cancer patients. The lack of any specific clinicodemographic features that correlates with FGFR1 amplification suggests that all squamous cell patients should be tested for this genomic change. SN - 1556-1380 UR - https://www.unboundmedicine.com/medline/citation/23154548/FGFR1_amplification_in_squamous_cell_carcinoma_of_the_lung_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1556-0864(15)33160-9 DB - PRIME DP - Unbound Medicine ER -